Navigation Links
Sales of Antiretroviral Agents Will Drive Substantial Six Percent Annual Growth in the HIV Drug Market Through 2013
Date:5/19/2009

By 2018, Gilead's Quad Will Become the Highest-Selling Antiretroviral in the World's Major Markets, According to a New Report from Decision Resources

WALTHAM, Mass., May 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that sales of antiretroviral agents will drive substantial six percent annual growth in the HIV drug market through 2013 but significant generic erosion of key therapies thereafter will slow annual growth to less than two percent from 2013 to 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Human Immunodeficiency Virus finds that continued increase in the uptake of Bristol-Myers Squibb/Gilead's Atripla will drive the agent to garner the highest sales of any antiretroviral in 2013. However, from 2013 to 2018, Gilead's Quad will make significant inroads in the HIV market and by 2018 will become the highest-selling antiretroviral drug in the world's major markets, according to the report. Quad will combine favorable safety and efficacy with the dosing convenience of a single daily pill regimen, making it an ideal product for treatment-naive patients.

"The largest commercial opportunities in the HIV market lie in the development of therapies with enhanced convenience, such as co-formulations that minimize the number of pills and frequency of dosing, especially safe and effective therapies that target treatment-naive patients -- the most lucrative segment of the market," said Decision Resources Analyst Jose Avalos, Ph.D. "In addition, agents with reduced long-term toxicities can differentiate themselves in this crowded market."

The report also finds that two novel classes of antiretroviral agents -- the integrase inhibitors and CCR5 antagonists -- have been received with different levels of enthusiasm among interviewed experts and prescribers. Merck's Isentress, the first integrase inhibitor on the market, has been received with great enthusiasm by physicians and patients because of its efficacy, safety, and simple dosing. In contrast, Pfizer's Selzentry, the first-in-class CCR5 antagonist, has experienced significant obstacles that include its limited patient eligibility and the lengthy tropism test required for its prescription. The landscape for CCR5 antagonists is expected to improve, however, once better tropism tests and improved protocols are established.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                          Decision Resources, Inc.
    Christopher Comfort                         Elizabeth Marshall
    781-296-2597                                781-296-2563
    ccomfort@dresources.com                     emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Psychemedics Corporation Announces Sales & Marketing Agreement With Bupa in UK
2. GeckoSystems Reveals Eldercare Capable Personal Robot Sales Forecasts
3. Herbal Supplement Sales Increase in US in 2008
4. U.S. Mobile Robot Co. Reveals Pacific Rim Sales Forecasts
5. Growth in Drug Sales of the Top 10 Pharmaceutical Companies Slowed to its Lowest Level in Years in 2008
6. OrthoSynetics Selects Landslides Sales P3 System as its Corporate Sales System
7. RBC Life Sciences North American Nutritional Supplements and Medical Products Sales Increased, Year Over Year, During the First Quarter of 2009
8. Milestone Scientific Reports Strong Sales Growth in First Quarter 2009 Results
9. Woodward Labs Reports Sales Spike for HandClens(R) Alcohol-Free Hand Sanitizer During Swine Flu Epidemic
10. Driven by Sales of Enbrel, Remicade and Humira, spondyloarthropathies Drug Market Grew to Nearly $2 Billion in 2008
11. Archi-Tech InView Now Supports Managed Care Data, Offering an Interactive Dashboard for On-Demand Sales Planning and Reporting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading ... to advocate for action towards gender equality at their inaugural Summit in New York ... globe, and reached a social audience of over 3 million. To watch the Mobilize ...
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... 12, 2017 , ... The American College of Medical Informatics (ACMI) will present ... the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... Collen, a pioneer in the field of medical informatics, this prestigious award is presented ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader ... a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were ... 11, 2017. , The annual award competition recognizes editorial and design excellence across a ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... Korea , Oct. 4, 2017  South Korean-based ... next-generation CPR training aide "cprCUBE" on Kickstarter. The device ... compression during cardiac arrests with better efficiency compared to ... also offers real-time feedback on efficacy of the compression ... crowdfunding campaign has a goal to raise $5,000. ...
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and Company ... results for the third quarter of 2017 on Tuesday, ... call on that day with the investment community and ... The conference call will begin at 9 a.m. ... access a live webcast of the conference call through ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
Breaking Medicine Technology: